Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13141649 | 0.85 | PTGS2 (0.40) | KDM4ECCR2ADRA1DADRA2AADRA1A | |
| SCHEMBL16019385 | 0.79 | SMN1; SMN2 (0.55) | KIF11PTGS2SMN1; SMN2 | |
| SCHEMBL18519118 | 0.79 | KDM4E (0.39) | KDM4ECCR2ADRA1DADRA2AADRA1A | |
| SCHEMBL16019362 | 0.78 | CCR2 (0.41) | KDM4ECCR2ADRA1DADRA2AADRA1A | |
| SCHEMBL16019376 | 0.78 | SMN1; SMN2 (0.37) | CCR2TSHRSMN1; SMN2HTT | |
| SCHEMBL5097716 | 0.74 | CCR2 (0.49) | KDM4ECCR2ADRA1DADRA2AADRA1A | |
| SCHEMBL16019394 | 0.74 | TRPV4 (0.43) | PTGS2 | |
| SCHEMBL16019390 | 0.74 | TDP1 (0.34) | SMN1; SMN2 | |
| SCHEMBL18897419 | 0.73 | CCR2 (0.42) | KDM4ECCR2ADRA1DADRA2AADRA1A | |
| SCHEMBL16019377 | 0.73 | ALDH1A1 (0.45) | KDM4ETSHRPTGS2SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-9693556-B2 | Herbicidal pyridazinone derivatives | SYNGENTA LIMITED (GB) | 2017-07-04 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | SYNGENTA LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256546-A1 | HERBICIDAL PYRIDAZINONE DERIVATIVES | PRDX6, PRDX1, CBR3 | KDM4E 1770/4885CCR2 511/4885ADRA1D 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.